leisure time -WSS

leisure time

author：Wikipedia 2025-09-14 21:54:56 - browse：1822

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： NIH documents show early flaws of $1.6 billion long Covid program

hotspot

WSS

How to increase colonoscopy rates? Looks like an AI can help

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Trump got a 'target letter.' What is one and what does it mean?

FDA's Pazdur wants cancer trials to range beyond China alone

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

Moonlake's readout produced a cash windfall. Risks remain

How to increase colonoscopy rates? Looks like an AI can help

Wildfire smoke exposes gaps in outdoor worker protections

Stanford president to resign after investigation of research

George Santos makes 1st court appearance after pleading not guilty to 13 counts

At ASCO, AstraZeneca reports strong data for breast cancer drug

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Plane’s emergency slide plummets from sky, hits Chicago home

Alkermes shareholders re

Seattle police shoot person suspected in downtown stabbing

explore

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Norman Reedus' Daryl Dixon

Let's speed up science by embracing open access publishing

States increasingly look to regulate hospital facility fees

Ultragenyx gene therapy for rare liver ailment succeeds in late

hotspot

knowledge

hotspot

hotspot